Reliance Trust Co. of Delaware grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,263 shares of the medical research company’s stock after buying an additional 614 shares during the quarter. Reliance Trust Co. of Delaware’s holdings in Amgen were worth $1,713,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Beutel Goodman & Co Ltd. purchased a new stake in shares of Amgen during the 2nd quarter valued at about $86,723,000. Natixis raised its position in Amgen by 2,612.1% in the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock worth $97,799,000 after purchasing an additional 510,281 shares during the period. Dimensional Fund Advisors LP raised its position in Amgen by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after purchasing an additional 343,690 shares during the period. Bank of Nova Scotia raised its position in Amgen by 234.2% in the 2nd quarter. Bank of Nova Scotia now owns 433,450 shares of the medical research company’s stock worth $80,011,000 after purchasing an additional 303,743 shares during the period. Finally, Royal London Asset Management Ltd. purchased a new stake in Amgen in the 2nd quarter worth about $54,522,000. Hedge funds and other institutional investors own 82.37% of the company’s stock.
Shares of AMGN stock opened at $187.06 on Monday. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08. The stock has a market capitalization of $119.20 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 1.95 and a beta of 1.37. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. The business had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.27 EPS. On average, equities analysts forecast that Amgen, Inc. will post 14.21 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 dividend on an annualized basis and a yield of 2.82%. Amgen’s dividend payout ratio is currently 41.97%.
A number of analysts recently weighed in on AMGN shares. Cann reissued a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research report on Monday, October 1st. Royal Bank of Canada reissued a “neutral” rating and issued a $193.00 price objective on shares of Amgen in a research report on Monday, September 10th. Oppenheimer reissued a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research report on Tuesday, August 28th. Jefferies Financial Group set a $220.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Monday, October 8th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $229.00 price objective on shares of Amgen in a research report on Friday, October 12th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $204.55.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
See Also: What Factors Can Affect Return on Equity?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.